Transcription-Driven Repurposing of Cardiotonic Steroids for Lithium Treatment of Severe Depression
Cells · 2025
DOI: 10.3390/cells14080575 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Richard Killick und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Healthy Brain Aging, IoPPN, King's College London, London SE5 9RT, UK. Hauptthemen laut MEDLINE: Drug Repositioning, Lithium, Transcription, Genetic, Cardiac Glycosides. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Themen: Depression
Abstract (Originalsprache)
Lithium is prescribed as a mood stabilizer for bipolar disorder and severe depression. However, the mechanism of action of lithium is unknown and there are major side effects associated with prolonged medication. This motivates a search for safer alternative drug repurposing candidates. Given that the drug mechanism may be encoded in transcriptional changes, we generated the gene expression profile for acute lithium treatment of cortical neuronal cultures. We found that the lithium-associated transcription response harbors a significant component that is the reverse of that seen in human brain samples from patients with major depression, bipolar disorder, and a mouse model of depression. Interrogating publicly available drug-driven expression data, we found that cardiotonic steroids drive gene expression in a correlated manner to our acute lithium profile. An analysis of the psychiatric medication cohort of the Norwegian Prescription Database showed that cardiotonic prescription is associated with a lower incidence of lithium prescription. Our transcriptional and epidemiological observations point towards cardiotonic steroids as possible repurposing candidates for lithium. These observations motivate a controlled trial to establish a causal connection and genuine therapeutic benefit in the context of depression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Healthy Brain Aging, IoPPN, King's College London, London SE5 9RT, UK.
- IHU HealthAge, Gérontopôle, Department of Geriatrics, CHU Toulouse, 31059 Toulouse, France.
- Social, Genetic & Developmental Psychiatry Centre, IoPPN, King's College London, London SE5 8AF, UK.
- MRC Centre for Neurodevelopmental Disorders, IoPPN, King's College London, London SE1 1UL, UK.
- Faculty of Medical Sciences, School of Biomedical, Nutritional and Sport Sciences, Newcastle University, Newcastle NE4 5TG, UK.
- Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, 4011 Stavanger, Norway.
ORCID-Profile: Richard Killick, Claudie Hooper, Christina Elliott, Svein R Kjosavik, Gareth Williams
Förderung
- Medical Research Council
Zitieren
APA
Killick, R., Hooper, C., Fernandes, C., Elliott, C., Aarsland, D., Kjosavik, S. R., Østerhus, R., & Williams, G. (2025). Transcription-Driven Repurposing of Cardiotonic Steroids for Lithium Treatment of Severe Depression. Cells. https://doi.org/10.3390/cells14080575
Vancouver
Killick R, Hooper C, Fernandes C, Elliott C, Aarsland D, Kjosavik SR, et al. Transcription-Driven Repurposing of Cardiotonic Steroids for Lithium Treatment of Severe Depression. Cells. 2025. doi:10.3390/cells14080575
BibTeX
@article{Killick2025,
author = {Killick, Richard and Hooper, Claudie and Fernandes, Cathy and Elliott, Christina and Aarsland, Dag and Kjosavik, Svein R and Østerhus, Ragnhild and Williams, Gareth},
title = {Transcription-Driven Repurposing of Cardiotonic Steroids for Lithium Treatment of Severe Depression},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14080575}
}
EUVIMED